Document is current
Any future updates will be listed below
-
Authors
Boutitah-Benyaich, Imane
Eixarch, Herena
Villacieros-Álvarez, Javier
Hervera, Arnau
Cobo-Calvo, Álvaro
Montalban, Xavier
Espejo, Carmen https://orcid.org/0000-0001-9949-5901
- License Information
-
More Information
Article History
Received: 19 December 2024
Revised: 23 June 2025
Accepted: 27 August 2025
First Online: 2 October 2025
Competing interests
: I.B., A.H., and A.C.C. have nothing to disclose. J.V.A. has received grants from Instituto de Salud Carlos III, Spain; FI21/00282. H.E. and C.E. hold a patent related to liposome immunotherapy for autoimmune diseases, licensed to Ahead Therapeuthics, SL. X.M. has received speaking honoraria and travel expenses for scientific meetings; has been a steering committee member of clinical trials; or has participated in advisory boards of clinical trials in recent years, such as Abbvie, Actelion, Alexion, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sandoz, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.
